Guardant Health, Inc. (NASDAQ:GH) Given Average Rating of “Moderate Buy” by Analysts

Guardant Health, Inc. (NASDAQ:GH) has been given a consensus recommendation of “Moderate Buy” by the twenty-five analysts that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, twenty-three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $155.6957.

GH has been the topic of several recent analyst reports. JPMorgan Chase & Co. boosted their price objective on Guardant Health from $130.00 to $135.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Guardant Health in a report on Tuesday, April 21st. BTIG Research lifted their target price on shares of Guardant Health from $160.00 to $190.00 and gave the stock a “buy” rating in a research report on Wednesday, July 1st. Citigroup boosted their price target on shares of Guardant Health from $150.00 to $215.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Finally, The Goldman Sachs Group initiated coverage on shares of Guardant Health in a research report on Friday, June 5th. They issued a “buy” rating and a $165.00 price target for the company.

Guardant Health Stock Down 1.0%

Shares of NASDAQ GH opened at $158.40 on Tuesday. The stock’s fifty day simple moving average is $128.92 and its 200 day simple moving average is $108.75. The stock has a market capitalization of $21.00 billion, a price-to-earnings ratio of -46.73 and a beta of 1.59. Guardant Health has a 52-week low of $40.35 and a 52-week high of $174.08.

Insider Activity at Guardant Health

In other news, Director Myrtle S. Potter sold 1,556 shares of the firm’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $131.16, for a total value of $204,084.96. Following the completion of the sale, the director owned 20,971 shares of the company’s stock, valued at $2,750,556.36. This trade represents a 6.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Michael Brian Bell sold 2,000 shares of Guardant Health stock in a transaction on Friday, June 5th. The shares were sold at an average price of $128.62, for a total value of $257,240.00. Following the transaction, the chief financial officer owned 47,509 shares in the company, valued at $6,110,607.58. This represents a 4.04% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 708,681 shares of company stock worth $90,566,438. Insiders own 5.60% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. V Square Quantitative Management LLC purchased a new stake in Guardant Health in the 4th quarter worth about $27,000. Chesapeake Asset Management LLC purchased a new position in Guardant Health during the 4th quarter valued at about $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new position in shares of Guardant Health in the 4th quarter valued at about $31,000. Elyxium Wealth LLC purchased a new stake in shares of Guardant Health in the fourth quarter worth approximately $35,000. Finally, Parallel Advisors LLC lifted its position in shares of Guardant Health by 164.7% in the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock worth $36,000 after purchasing an additional 219 shares in the last quarter. 92.60% of the stock is owned by institutional investors and hedge funds.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.